Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - A case series

• Main Authors: Tirza Wouters (Author), Natasja Hendriks (Author), Margot Koeneman (Author), Arnold-Jan Kruse (Author), Anna van de Sande (Author), Heleen J. van Beekhuizen (Author), Kees G. Gerestein (Author), Ruud L.M. Bekkers (Author), Jurgen M.J. Piek (Author)
• Format: Book
• Published: Elsevier, 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Treatment for cervical intraepithelial neoplasia (CIN) often consists of an excisional procedure. However, less invasive treatment methods have been explored, such as topical treatment with imiquimod cream. Imiquimod has been proven to be effective in the regression of vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VAIN). Previous studies have investigated the effect of imiquimod in CIN and showed well tolerated adverse effects. During a current study in the Netherlands, a number of adverse events have occurred. This case series presents a selection of these. Gynaecologists should be aware of the possible adverse effects of topical treatment with imiquimod cream. Keywords: Imiquimod, Aldara, Side effects, HSIL, CIN, Nausea

Item Description

2214-9112
10.1016/j.crwh.2019.e00105